Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients
Randomized Study Evaluating the Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients
Sponsor: Fondation de France
This PHASE3 trial investigates Asthenia and Neoplasms and is currently terminated or withdrawn. Fondation de France leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fondation de France
- Ligue contre le cancer, France
- University Hospital, Grenoble
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Annemasse, France , Bordeaux, France , Grenoble, France , Lille, France , Lyon, France , Montpellier, France , Paris, France , Passy, France , Saint-Etienne, France , Thonon-les-Bains, France and 1 more location